Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.

Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM

Open source

DOI: 10.1182/bloodadvances.2022008625
Published: 2023 Jun 13
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2022008625,
  title = {Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.},
  author = {Saliba AN and Kaufmann SH and Stein EM and Patel PA and Baer MR and Stock W and Deininger M and Blum W and Schiller GJ and Olin RL and Litzow MR and Lin TL and Ball BJ and Boyiadzis MM and Traer E and Odenike O and Arellano ML and Walker A and Duong VH and Kovacsovics T and Collins RH and Shoben AB and Heerema NA and Foster MC and Peterson KL and Schneider PA and Martycz M and Gana TJ and Rosenberg L and Marcus S and Yocum AO and Chen T and Stefanos M and Mims AS and Borate U and Burd A and Druker BJ and Levine RL and Byrd JC and Foran JM},
  year = {2023},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2022008625},
  url = {https://doi.org/10.1182/bloodadvances.2022008625}
}

RIS

TY  - JOUR
TI  - Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
AU  - Saliba AN
AU  - Kaufmann SH
AU  - Stein EM
AU  - Patel PA
AU  - Baer MR
AU  - Stock W
AU  - Deininger M
AU  - Blum W
AU  - Schiller GJ
AU  - Olin RL
AU  - Litzow MR
AU  - Lin TL
AU  - Ball BJ
AU  - Boyiadzis MM
AU  - Traer E
AU  - Odenike O
AU  - Arellano ML
AU  - Walker A
AU  - Duong VH
AU  - Kovacsovics T
AU  - Collins RH
AU  - Shoben AB
AU  - Heerema NA
AU  - Foster MC
AU  - Peterson KL
AU  - Schneider PA
AU  - Martycz M
AU  - Gana TJ
AU  - Rosenberg L
AU  - Marcus S
AU  - Yocum AO
AU  - Chen T
AU  - Stefanos M
AU  - Mims AS
AU  - Borate U
AU  - Burd A
AU  - Druker BJ
AU  - Levine RL
AU  - Byrd JC
AU  - Foran JM
PY  - 2023
JO  - Blood advances
DO  - 10.1182/bloodadvances.2022008625
UR  - https://doi.org/10.1182/bloodadvances.2022008625
ER  -

APA

AN, S., SH, K., EM, S., PA, P., MR, B., W, S., M, D., W, B., GJ, S., RL, O., MR, L., TL, L., BJ, B., MM, B., E, T., O, O., ML, A., A, W., VH, D., T, K., RH, C., AB, S., NA, H., MC, F., KL, P., PA, S., M, M., TJ, G., L, R., S, M., AO, Y., T, C., M, S., AS, M., U, B., A, B., BJ, D., RL, L., JC, B., & JM, F. (2023). Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.. Blood advances. https://doi.org/10.1182/bloodadvances.2022008625

Source records

pubmed · retrieved 2026-09-26T16:16:29.110Z